NCT03142334, Pembrolizumab, buyrak hujayrali karsinoma

Pembrolizumab buyrak hujayrali karsinomani adjuvant davolash uchun tasdiqlangan

2022 yil yanvar: Pembrolizumab (Keytruda, Merck) oziq-ovqat va farmatsevtika idorasi tomonidan buyrak hujayrali karsinomasi (RCC) bilan og'rigan bemorlarni adjuvan davolash uchun tasdiqlangan.

KEYTRUDA, Lenvatinib, Lenvatinib va ​​pembrolizumab, Dangasalik, Tashkilot,, buyrak hujayrali karsinoma

FDA rivojlangan buyrak hujayrali karsinomasi uchun lenvatinib va ​​pembrolizumab kombinatsiyasini ma'qulladi.

2021 yil avgust: Lenvatinib (Lenvima, Eisai) va pembrolizumab (Keytruda, Merck) kombinatsiyasi oziq-ovqat va farmatsevtika idorasi tomonidan ilgari buyrak hujayrali karsinomli katta yoshli bemorlarni davolash uchun tasdiqlangan.

AVEO farmatsevtika, Fotivda, kinaz inhibitori, refrakter rivojlangan buyrak hujayrali karsinomasi, buyrak hujayrali karsinoma, tivozanib

Tivozanib FDA tomonidan retsidiv yoki refrakter rivojlangan buyrak hujayrali karsinomasini davolash uchun tasdiqlangan.

2021 yil avgust: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), kinaz inhibitori, ikki yoki undan ortiq tizimli tizimli kasalliklardan keyin qaytalanuvchi yoki refrakter rivojlangan buyrak hujayrali karsinomasi (RCC) bo'lgan kattalardagi bemorlar uchun FDA tomonidan tasdiqlangan.

Buyrak saratonining 8 asosiy sababi

Many patients with kidney cancer do not know why they have this disease, meaning the causes of kidney cancer are relatively unknown. After the examination, they will be very surprised. Some even feel that the kidney is not a probl..